Nuvelo (Nasdaq: NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (254)	1/21/2003 8:45:55 PM
From: SemiBull	Read Replies (1) of 286

Variagenics Rebuffs Acacia Offer; Backs Hyseq Merger Tuesday January 21, 11:17 am ET CAMBRIDGE, Mass. (Dow Jones)--Variagenics Inc. rebuffed an unsolicited offer from Acacia Research Corp. and urged Variagenics shareholders to approve an existing merger plan with Hyseq Pharmaceuticals Inc. Variagenics said in a press release Tuesday that it received the offer Thursday from Acacia Research's CombiMatrix unit. Variagenics, which is developing genetic tests for different kinds of cancer, said its board stood by the original plan after reviewing concerns about Acacia's capital structure, liquidity and whether Acacia's biochip technology platform would find commercial success. Variagenics said Nov. 11 that it agreed to be acquired by Hyseq for $55.9 million in stock.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next